Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | EVP, General Counsel, Corp Sec | March 14, 2026 | March 17, 2026 |
| INSULET CORPPODD · Entity 3516 | SVP, Secretary and GC | April 02, 2019 | April 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date March 14, 2026 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,570 |
Ending reported balance
After 2026-03-15 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-03-14 · Exercise / conversion · Acquired 9,388 · Balance 62,488 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. Row 2 · 2026-03-14 · Grant · Acquired 4,694 · Balance 67,182 F2: On March 14, 2025, the Reporting Person was granted 14,082 performance-based phantom RSUs ("PSUs") with vesting contingent upon the achievement of pre-established performance and strategic targets. This transaction represents the first vesting installment of such PSU award. Row 3 · 2026-03-14 · Tax withholding · Disposed 4,168 · Balance 63,014 F3: Reflects an aggregate of 4,694 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs and PSUs that vested on March 14, 2026. Row 4 · 2026-03-15 · Exercise / conversion · Acquired 6,449 · Balance 69,463 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. Row 5 · 2026-03-15 · Tax withholding · Disposed 1,893 · Balance 67,570 F4: Reflects an aggregate of 1,893 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2026. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 18,777 |
Reported balance
After 2026-03-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-14 · Exercise / conversion · Disposed 9,388 · Balance 18,777 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. F5: On March 14, 2025, the Reporting Person was granted 28,165 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 6,448 |
Reported balance
After 2026-03-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-03-15 · Exercise / conversion · Disposed 6,449 · Balance 6,448 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. F6: On March 15, 2024, the Reporting Person was granted 19,345 RSUs vesting in three equal annual installments beginning on March 15, 2025. This transaction reflects the second vesting installment of such RSU award. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.
F2: On March 14, 2025, the Reporting Person was granted 14,082 performance-based phantom RSUs ("PSUs") with vesting contingent upon the achievement of pre-established performance and strategic targets. This transaction represents the first vesting installment of such PSU award.
F3: Reflects an aggregate of 4,694 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs and PSUs that vested on March 14, 2026.
F4: Reflects an aggregate of 1,893 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2026.
F5: On March 14, 2025, the Reporting Person was granted 28,165 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award.
F6: On March 15, 2024, the Reporting Person was granted 19,345 RSUs vesting in three equal annual installments beginning on March 15, 2025. This transaction reflects the second vesting installment of such RSU award.
INSULET CORP
Report date April 02, 2019 · Filed April 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,433 |
Last balance in matching sequence
After 2019-04-02 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2019-04-02 · Exercise / conversion · Acquired 7,395 · Balance 37,828 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2018. F2: Includes 1,443 restricted stock units granted on February 22, 2017, which vest on February 22, 2020; and 1,790 restricted stock units granted on February 14, 2018, which vest as to one-half of the total units on February 14, 2020 and one-half of the total units on February 14, 2021, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. Row 2 · 2019-04-02 · Sale · Disposed 7,395 · Balance 30,433 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2018. F2: Includes 1,443 restricted stock units granted on February 22, 2017, which vest on February 22, 2020; and 1,790 restricted stock units granted on February 14, 2018, which vest as to one-half of the total units on February 14, 2020 and one-half of the total units on February 14, 2021, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.98 · Expires 2025-06-29 | Direct | 3,698 |
Reported balance
After 2019-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-04-02 · Exercise / conversion · Disposed 7,395 · Balance 3,698 F3: This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2018.
F2: Includes 1,443 restricted stock units granted on February 22, 2017, which vest on February 22, 2020; and 1,790 restricted stock units granted on February 14, 2018, which vest as to one-half of the total units on February 14, 2020 and one-half of the total units on February 14, 2021, subject to continued employment. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date.
F3: This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2026 Filed Mar 17, 2026 23:47 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 6,449 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-111511 · ownership.xml · derivative · entry 7 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,448 Underlying: Common Stock · 6,449 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. F6 · derivative.exercise_date: On March 15, 2024, the Reporting Person was granted 19,345 RSUs vesting in three equal annual installments beginning on March 15, 2025. This transaction reflects the second vesting installment of such RSU award. F6 · derivative.expiration_date: On March 15, 2024, the Reporting Person was granted 19,345 RSUs vesting in three equal annual installments beginning on March 15, 2025. This transaction reflects the second vesting installment of such RSU award. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 23:47 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 1,893 | $14.20 | $26,880.60 |
DisclosureSEC source: 0001193125-26-111511 · ownership.xml · nonDerivative · entry 5 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,570 F4 · shares: Reflects an aggregate of 1,893 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2026. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 23:47 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 6,449 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-111511 · ownership.xml · nonDerivative · entry 4 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 23:47 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 9,388 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-111511 · ownership.xml · derivative · entry 6 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,777 Underlying: Common Stock · 9,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: On March 14, 2025, the Reporting Person was granted 28,165 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award. F5 · derivative.expiration_date: On March 14, 2025, the Reporting Person was granted 28,165 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 23:47 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 4,168 | $14.20 | $59,185.60 |
DisclosureSEC source: 0001193125-26-111511 · ownership.xml · nonDerivative · entry 3 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,014 F3 · shares: Reflects an aggregate of 4,694 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs and PSUs that vested on March 14, 2026. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 23:47 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 4,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-111511 · ownership.xml · nonDerivative · entry 2 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,182 F2 · shares: On March 14, 2025, the Reporting Person was granted 14,082 performance-based phantom RSUs ("PSUs") with vesting contingent upon the achievement of pre-established performance and strategic targets. This transaction represents the first vesting installment of such PSU award. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 23:47 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 9,388 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-111511 · ownership.xml · nonDerivative · entry 1 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:25 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 5,465 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-102240 · ownership.xml · derivative · entry 3 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,465 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: On March 9, 2023, the Reporting Person was granted 16,395 RSUs vesting in three equal annual installments beginning on March 9, 2024. This transaction reflects the third and final vesting installment of such RSU award. F4 · derivative.expiration_date: On March 9, 2023, the Reporting Person was granted 16,395 RSUs vesting in three equal annual installments beginning on March 9, 2024. This transaction reflects the third and final vesting installment of such RSU award. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:25 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 1,919 | $14.96 | $28,708.24 |
DisclosureSEC source: 0001193125-26-102240 · ownership.xml · nonDerivative · entry 2 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,100 F3 · shares: Reflects an aggregate of 1,919 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2026. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:25 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 5,465 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-102240 · ownership.xml · nonDerivative · entry 1 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,019 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. F2 · balance_after: Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 800 shares purchased on May 14, 2025 and 800 shares purchased on November 14, 2025. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 21:16 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 6,448 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001532 · ownership.xml · derivative · entry 5 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,897 Underlying: Common Stock · 6,448 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025. F6 · derivative.expiration_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 21:16 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 1,893 | $15.91 | $30,117.63 |
DisclosureSEC source: 0001171843-25-001532 · ownership.xml · nonDerivative · entry 2 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,954 F2 · shares: Reflects an aggregate of 1,893 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2025. F3 · price: Reflects the closing price of ANIK common stock on March 14, 2025, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 21:16 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 6,448 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001532 · ownership.xml · nonDerivative · entry 1 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the first vesting installment of RSUs granted on March 15, 2024, which the Company elected to settle in shares. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:16 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 13,669 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001532 · ownership.xml · derivative · entry 4 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,669 Underlying: Common Stock · 13,669 shares Expires not disclosed F5 · derivative.exercise_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on the vest date. The 13,669 RSUs represent the Target number of shares that may be earned in conjunction with certain market metrics prescribed under the terms of the performance-based phantom RSU award. The award shall cliff vest on the 3rd anniversary of the grant date, subject to the Compensation Committee's determination of achievement of the award prior to the vest date. The number of shares earned and subject to vest, as determined by the Compensation Committee, may be in a range from Threshold (50% of Target) to Maximum (200% of Target). No shares shall vest for achievement under Threshold. F5 · derivative.expiration_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on the vest date. The 13,669 RSUs represent the Target number of shares that may be earned in conjunction with certain market metrics prescribed under the terms of the performance-based phantom RSU award. The award shall cliff vest on the 3rd anniversary of the grant date, subject to the Compensation Committee's determination of achievement of the award prior to the vest date. The number of shares earned and subject to vest, as determined by the Compensation Committee, may be in a range from Threshold (50% of Target) to Maximum (200% of Target). No shares shall vest for achievement under Threshold. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:16 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 28,165 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001532 · ownership.xml · derivative · entry 3 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,165 Underlying: Common Stock · 28,165 shares Expires not disclosed F4 · derivative.exercise_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 14, 2026. F4 · derivative.expiration_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 14, 2026. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 21:18 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 7,663 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001468 · ownership.xml · derivative · entry 3 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,663 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. F4 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 21:18 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 2,250 | $16.79 | $37,777.50 |
DisclosureSEC source: 0001171843-25-001468 · ownership.xml · nonDerivative · entry 2 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,399 F2 · shares: Reflects an aggregate of 2,250 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 11, 2025. F3 · price: Reflects the closing price of ANIK common stock on March 11, 2025, the trading day to which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 21:18 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 7,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001468 · ownership.xml · nonDerivative · entry 1 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,649 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the third and final vesting installment of RSUs granted on March 11, 2022. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 21:17 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 5,465 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001405 · ownership.xml · derivative · entry 3 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,465 Underlying: Common Stock · 5,465 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024. F5 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 21:17 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 1,604 | $16.62 | $26,658.48 |
DisclosureSEC source: 0001171843-25-001405 · ownership.xml · nonDerivative · entry 2 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,986 F3 · shares: Reflects an aggregate of 1,604 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2025. F4 · price: Reflects the closing price of ANIK common stock on March 7, 2025, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 21:17 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 5,465 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001405 · ownership.xml · nonDerivative · entry 1 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the second vesting installment of RSUs granted on March 9, 2023. F2 · balance_after: Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 800 shares purchased on May 14, 2024 and 330 shares purchased on November 14, 2024. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 21:17 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 46,875 | $0.00 Strike: $27.98 | $0.00 |
DisclosureSEC source: 0001171843-24-001460 · ownership.xml · derivative · entry 2 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,875 Underlying: Common Stock · 46,875 shares Expires 2034-03-11 F2 · derivative.exercise_price: Represents a 10% premium above the closing price of Anika's common stock on the date of grant. F3 · derivative.exercise_date: The premium priced stock options vest in three equal annual installments beginning on March 15, 2025. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 21:17 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 19,345 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001460 · ownership.xml · derivative · entry 1 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,345 Underlying: Common Stock · 19,345 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:03 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 7,662 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001306 · ownership.xml · derivative · entry 9 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,663 Underlying: Common Stock · 7,662 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. F12 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:03 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 5,465 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001306 · ownership.xml · derivative · entry 8 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,930 Underlying: Common Stock · 5,465 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024. F11 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:03 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 3,682 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001306 · ownership.xml · derivative · entry 7 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. F10 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:03 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 2,250 | $25.79 | $58,027.50 |
DisclosureSEC source: 0001171843-24-001306 · ownership.xml · nonDerivative · entry 6 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,995 F8 · shares: Reflects an aggregate of 2,250 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 11, 2024. F9 · price: Reflects the closing price of ANIK common stock on March 11, 2024, the trading day on which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:03 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 7,662 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001306 · ownership.xml · nonDerivative · entry 5 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · shares: Reflects the second vesting installment of RSUs granted on March 11, 2022. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:03 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 1,605 | $25.42 | $40,799.10 |
DisclosureSEC source: 0001171843-24-001306 · ownership.xml · nonDerivative · entry 4 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,583 F6 · shares: Reflects an aggregate of 1,605 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2024. F4 · price: Reflects the closing price of ANIK common stock on March 8, 2024, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:03 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 5,465 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001306 · ownership.xml · nonDerivative · entry 3 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Reflects the first vesting installment of RSUs granted on March 9, 2023. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:03 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 1,081 | $25.42 | $27,479.02 |
DisclosureSEC source: 0001171843-24-001306 · ownership.xml · nonDerivative · entry 2 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,723 F3 · shares: Reflects an aggregate of 1,081 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2024. F4 · price: Reflects the closing price of ANIK common stock on March 8, 2024, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:03 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 3,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-001306 · ownership.xml · nonDerivative · entry 1 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the third and final vesting installment of Restricted Stock Units (RSUs) granted on March 9, 2021. F2 · balance_after: Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 642 shares on May 12, 2023 and 192 shares on November 14, 2023. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 7,663 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-001685 · ownership.xml · derivative · entry 3 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,325 Underlying: Common Stock · 7,663 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. F4 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 2,250 | $26.10 | $58,725.00 |
DisclosureSEC source: 0001171843-23-001685 · ownership.xml · nonDerivative · entry 2 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,288 F2 · shares: Reflects an aggregate of 2,250 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 11, 2023. F3 · price: Reflects the closing price of ANIK common stock on March 10, 2023, the trading day immediately preceding the date on which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:46 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 7,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-001685 · ownership.xml · nonDerivative · entry 1 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the first vesting installment of Restricted Stock Units (RSUs) granted on March 11, 2022. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 21:51 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 3,683 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-001596 · ownership.xml · derivative · entry 5 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,682 Underlying: Common Stock · 3,683 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. F7 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 21:51 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 35,790 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001171843-23-001596 · ownership.xml · derivative · entry 4 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,790 Underlying: Common Stock · 35,790 shares Expires 2033-03-09 F5 · derivative.exercise_price: Represents a 10% premium above the closing price of Anika's common stock on the date of grant. F6 · derivative.exercise_date: The premium priced stock options vest in three equal annual installments beginning on March 9, 2024. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 21:51 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 16,395 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-001596 · ownership.xml · derivative · entry 3 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,395 Underlying: Common Stock · 16,395 shares Expires not disclosed F4 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024. F4 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 21:51 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 1,081 | $26.91 | $29,089.71 |
DisclosureSEC source: 0001171843-23-001596 · ownership.xml · nonDerivative · entry 2 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,875 F2 · shares: Reflects an aggregate of 1,081 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2023. F3 · price: Reflects the closing price of ANIK common stock on March 9, 2023, the trading day on which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 09, 2023 Filed Mar 10, 2023 21:51 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 3,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-001596 · ownership.xml · nonDerivative · entry 1 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the second vesting installment of Restricted Stock Units (RSUs) granted on March 9, 2021. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:34 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 2,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-001480 · ownership.xml · derivative · entry 3 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vested in three equal annual installments beginning March 4, 2021. F5 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vested in three equal annual installments beginning March 4, 2021. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:34 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 734 | $31.59 | $23,187.06 |
DisclosureSEC source: 0001171843-23-001480 · ownership.xml · nonDerivative · entry 2 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,273 F3 · shares: Reflects an aggregate of 734 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 4, 2023. F4 · price: Reflects the closing price of ANIK common stock on March 3, 2023, the trading day on which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:34 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-23-001480 · ownership.xml · nonDerivative · entry 1 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the third and final vesting installment of Restricted Stock Units (RSUs) granted on March 4, 2020. F2 · balance_after: Includes 640 shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan on May 13, 2022. Read SEC document |
| May 11, 2022 Filed May 12, 2022 12:30 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | PurchaseCommon Stock | 1,500 | $21.37 | $32,055.00 |
DisclosureSEC source: 0001171843-22-003615 · ownership.xml · nonDerivative · entry 1 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,867 Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 13:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | PurchaseCommon Stock | 1,500 | $26.65 | $39,978.00 |
DisclosureSEC source: 0001171843-22-001915 · ownership.xml · nonDerivative · entry 1 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,367 F1 · price: On March 14, 2022, Mr. Colleran purchased 1,500 shares in multiple trades ranging from $26.58 to $26.71. The price reported above reflects the weighted average purchase price. Mr. Colleran undertakes to provide the Securities and Exchange Commission staff, the issuer, or any security holder, upon request, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 21:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 35,864 | $0.00 Strike: $28.14 | $0.00 |
DisclosureSEC source: 0001171843-22-001906 · ownership.xml · derivative · entry 2 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,864 Underlying: Common Stock · 35,864 shares Expires 2032-03-11 F2 · derivative.exercise_price: Represents a 10% premium above the closing price of Anika's common stock on the date of grant. F3 · derivative.exercise_date: The premium priced stock options vest in three equal annual installments beginning on March 11, 2023. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 21:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 22,988 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-22-001906 · ownership.xml · derivative · entry 1 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,988 Underlying: Common Stock · 22,988 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 22:36 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 3,682 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-22-001810 · ownership.xml · derivative · entry 3 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,365 Underlying: Common Stock · 3,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. F4 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 22:36 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 1,081 | $26.22 | $28,343.82 |
DisclosureSEC source: 0001171843-22-001810 · ownership.xml · nonDerivative · entry 2 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,867 F2 · shares: Reflects an aggregate of 1,081 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2022. F3 · price: Reflects the closing price of ANIK common stock on March 9, 2022, the trading day on which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 22:36 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 3,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-22-001810 · ownership.xml · nonDerivative · entry 1 Colleran David · CIK 0001646558 · EVP, General Counsel, Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the first vesting installment of Restricted Stock Units (RSUs) granted on March 9, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.